title: The Piccolo Intronic Single Nucleotide Polymorphism rs13438494 Regulates Dopamine and Serotonin Uptake and Shows Associations with Dependence-Like Behavior in Genomic Association Study.
abstract: Piccolo (PCLO) inhibits methamphetamine-induced neuropharmacological effects via modulation of dopamine (DA) uptake and regulation of the transport of synaptic vesicles in neuronal cells. Clinical studies have recently suggested that the single nucleotide polymorphism (SNP) rs13438494 in the intron 24 of the PCLO gene is associated with psychiatric disorder, in the meta-analysis of GWAS. Therefore, in this study, we attempted to evaluate the possible role of the PCLO SNP in the mechanisms of uptake of monoamines. To characterize rs13438494 in the PCLO gene, we constructed plasmids carrying either the C or A allele of the SNP and transiently transfected them into SH-SY5Y cells to analyze genetic effects on the splicing of PCLO mRNA. The C and A allele constructs produced different composition of the transcripts, indicating that the intronic SNP does affect the splicing pattern. We also transfected DA and serotonin (5-hydroxytryptamine; 5- HT) transporters into cells and analyzed their uptakes to elucidate the association to psychiatric disorders. In the cells transfected with the C allele, both the DA and 5-HT uptake were enhanced compared to the A allele. We also conducted a clinical study, in order to clarify the genetic associations. PCLO rs13438494 exhibits a relationship with the symptoms of drug dependence or related parameters, such as the age of first exposure to methamphetamine, eating disorders, tobacco dependence and fentanyl requirement. Our findings suggest that rs13438494 is associated with drug abuse and contributes to the pathogenesis of psychiatric disorders via modulation of neurotransmitter turnover.
authors.forename: K
authors.initials: K
authors.lastname: Uno
authors.forename: D
authors.initials: D
authors.lastname: Nishizawa
authors.forename: S
authors.initials: S
authors.lastname: Seo
authors.forename: K
authors.initials: K
authors.lastname: Takayama
authors.forename: S
authors.initials: S
authors.lastname: Matsumura
authors.forename: N
authors.initials: N
authors.lastname: Sakai
authors.forename: K
authors.initials: K
authors.lastname: Ohi
authors.forename: T
authors.initials: T
authors.lastname: Nabeshima
authors.forename: R
authors.initials: R
authors.lastname: Hashimoto
authors.forename: N
authors.initials: N
authors.lastname: Ozaki
authors.forename: J
authors.initials: J
authors.lastname: Hasegawa
authors.forename: N
authors.initials: N
authors.lastname: Sato
authors.forename: F
authors.initials: F
authors.lastname: Tanioka
authors.forename: H
authors.initials: H
authors.lastname: Sugimura
authors.forename: K-I-
authors.initials: KI
authors.lastname: Fukuda
authors.forename: S
authors.initials: S
authors.lastname: Higuchi
authors.forename: H
authors.initials: H
authors.lastname: Ujike
authors.forename: T
authors.initials: T
authors.lastname: Inada
authors.forename: N
authors.initials: N
authors.lastname: Iwata
authors.forename: I
authors.initials: I
authors.lastname: Sora
authors.forename: M
authors.initials: M
authors.lastname: Iyo
authors.forename: N
authors.initials: N
authors.lastname: Kondo
authors.forename: M-J
authors.initials: MJ
authors.lastname: Won
authors.forename: N
authors.initials: N
authors.lastname: Naruse
authors.forename: K
authors.initials: K
authors.lastname: Uehara-Aoyama
authors.forename: M
authors.initials: M
authors.lastname: Itokawa
authors.forename: M
authors.initials: M
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: Y
authors.initials: Y
authors.lastname: Miyamoto
authors.affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan. nitta@pha.u-toyama.ac.jp.
authors.forename: A
authors.initials: A
authors.lastname: Nitta
mesh_terms: D017668:Age of Onset; D019969:Amphetamine-Related Disorders / Q000235:genetics*; D000701:Analgesics, Opioid / Q000627:therapeutic use; D000855:Anorexia / Q000235:genetics*; D003598:Cytoskeletal Proteins / Q000235:genetics*; D004298:Dopamine / Q000378:metabolism*; D005283:Fentanyl / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D055106:Genome-Wide Association Study; D057809:HEK293 Cells; D006801:Humans; D007438:Introns; D009479:Neuropeptides / Q000235:genetics*; D057909:Orthognathic Surgery; D020641:Polymorphism, Single Nucleotide; D012701:Serotonin / Q000378:metabolism*
chemical_list: D000701:Analgesics, Opioid; D003598:Cytoskeletal Proteins; D009479:Neuropeptides; C498630:PCLO protein, human; D012701:Serotonin; D005283:Fentanyl; D004298:Dopamine